RecruitingPhase 2NCT07461831

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma: A Prospective, Single-Arm, Single-Center, Phase 2 Trial

Sponsor

Beijing Tongren Hospital

Enrollment

100 participants

Start Date

Feb 1, 2022

Study Type

INTERVENTIONAL

Conditions

Large B-Cell Lymphoma (LBCL)

Summary

CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B- NHL. In this prospective phase 2 clinical trial, the investigators aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory Large B cell lymphoma.

Eligibility

Min Age: 14 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of immune cell therapy called bispecific CAR-T cell therapy for people with a type of blood cancer called large B-cell lymphoma that has come back or stopped responding to treatment. These specially engineered immune cells target two proteins on cancer cells (CD19 and CD22) at the same time, which may make the treatment more effective. **You may be eligible if...** - You are between 14 and 85 years old with an expected survival of more than 3 months - You have large B-cell lymphoma that has relapsed (come back) or is refractory (not responding to treatment) - Your cancer tests positive for the CD19 protein - You are reasonably functional (ECOG score 0–2) - Your heart, liver, kidney, and blood counts meet the required levels **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have serious allergies or another active cancer - You have a severe mental disorder - You have serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.